Vesicor Therapeutics
San Gabriel, US · California corporation
Vesicor develops precision-engineered cellular microvesicles that deliver p53 mRNA to cancer cells using a non-viral, immune-silent platform, aiming to restore tumor suppression in advanced solid tumors. Its lead candidate, ecm-RV/p53, and broader platform are designed for oncology therapeutics and multiple payload types.
Founders & leadership
MB
Michael BowenExecutive
WJ
Warren Jr. HosseinionExecutive
LF
Luo FengExecutive
WH
Warren HosseinionExecutive
WH
Warren HosseinionnNamed on SEC filing
Board
OL
Oded LevyBoard director
Reported raises · per SEC filings
Form D private placements$715K disclosed across 2 rounds · 2023–2024
▶$515KraisedMay 2025 · 12 investors · BiotechnologyRule 506(b)
▶$515KraisedMay 2025 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael BowenExecutive Officer
- Warren Jr. HosseinionExecutive Officer
- Oded LevyDirector
- Luo FengExecutive Officer, Director
- Warren HosseinionDirector
- Offering amount
- $3M
- Amount sold
- $515K
- Minimum investment
- $20K
- Sales commissions
- $300K
- Placement agents
- Altitude Capital Group LLC
- First sale
- Jul 2024
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$200KraisedSep 2023 · 2 investors · BiotechnologyRule 506(b)
▶$200KraisedSep 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael BowenExecutive Officer
- Luo FengExecutive Officer, Director
- Warren Jr. HosseinionExecutive Officer
- Oded LevyDirector
- Warren HosseinionnDirector
- Offering amount
- $3M
- Amount sold
- $200K
- Minimum investment
- $50K
- Sales commissions
- $300K
- Placement agents
- Emerson Equity LLC
- First sale
- Sep 2023
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapVivace Therapeutics8 shared keywordsVivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types. The company adopts a capital-efficient approach to advance novel cancer therapeutics, with potential applications also in fibrotic disease.
Capricor6 shared keywordsCapricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.
Vividion Therapeutics6 shared keywordsVividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins. The company operates across the full drug development spectrum from discovery to clinical development.
Companies competing with Vesicor Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Vesicor Therapeutics do?
- Vesicor develops precision-engineered cellular microvesicles that deliver p53 mRNA to cancer cells using a non-viral, immune-silent platform, aiming to restore tumor suppression in advanced solid tumors. Its lead candidate, ecm-RV/p53, and broader platform are designed for oncology therapeutics and multiple payload types.
- How much funding has Vesicor Therapeutics raised?
- Vesicor Therapeutics has disclosed $715K raised across 2 rounds.
- Where is Vesicor Therapeutics headquartered?
- Vesicor Therapeutics is headquartered in San Gabriel, US.